Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) hit a new 52-week high on Wednesday . The company traded as high as C$0.10 and last traded at C$0.08, with a volume of 155000 shares changing hands. The stock had previously closed at C$0.09.
Hemostemix Stock Up 6.3 %
The firm’s 50 day simple moving average is C$0.09 and its 200-day simple moving average is C$0.06. The company has a market capitalization of C$7.41 million, a PE ratio of -4.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Are Penny Stocks a Good Fit for Your Portfolio?
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Penny Stocks Ready to Break Out in 2025
- The 3 Best Retail Stocks to Shop for in August
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
